diethylcarbamazine has been researched along with Parasitemia in 17 studies
Diethylcarbamazine: An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.
Parasitemia: The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Repeated, single, oral doses of combinations of ivermectin, diethylcarbamazine (DEC) or albendazole are recognized as important tools for parasite control in lymphatic filariasis." | 9.09 | Two-year follow-up of the microfilaraemia of asymptomatic brugian filariasis, after treatment with two, annual, single doses of ivermectin, diethylcarbamazine and albendazole, in various combinations. ( Babu, BS; John, A; Kumaraswami, V; Shenoy, RK; Suma, TK, 2000) |
| "The long-term effect of three different strategies for mass diethylcarbamazine (DEC) administration in bancroftian filariasis was assessed 10 years after start of treatment in three endemic communities in Tanzania." | 7.72 | Long-term effect of three different strategies for mass diethylcarbamazine administration in bancroftian filariasis: follow-up at 10 years after treatment. ( Magesa, SM; Meyrowitsch, DW; Simonsen, PE, 2004) |
| "A microfilaria survey was conducted in Trinidad in 1992, 12 years after mass treatment with spaced doses of diethylcarbamazine citrate (DEC-C) for the control of Bancroftian filariasis; 348 persons were examined using thick blood smears and a membrane filtration technique." | 7.69 | Mass chemotherapy with diethylcarbamazine for the control of Bancroftian filariasis: a twelve-year follow-up in northern Trinidad, including observations on Mansonella ozzardi. ( Chadee, DD; Doon, R; Nathan, MB; Rawlins, SC; Tilluckdharry, CC, 1995) |
| "Repeated, single, oral doses of combinations of ivermectin, diethylcarbamazine (DEC) or albendazole are recognized as important tools for parasite control in lymphatic filariasis." | 5.09 | Two-year follow-up of the microfilaraemia of asymptomatic brugian filariasis, after treatment with two, annual, single doses of ivermectin, diethylcarbamazine and albendazole, in various combinations. ( Babu, BS; John, A; Kumaraswami, V; Shenoy, RK; Suma, TK, 2000) |
| "The long-term effect of three different strategies for mass diethylcarbamazine (DEC) administration in bancroftian filariasis was assessed 10 years after start of treatment in three endemic communities in Tanzania." | 3.72 | Long-term effect of three different strategies for mass diethylcarbamazine administration in bancroftian filariasis: follow-up at 10 years after treatment. ( Magesa, SM; Meyrowitsch, DW; Simonsen, PE, 2004) |
| "The persistence of parasite-specific cellular hyporesponsiveness after clearance of blood microfilariae (mf) was studied in 18 individuals who had been treated with a single dose of ivermectin, diethylcarbamazine, or a combination 2-3 years previously and who had initially cleared their parasitemia." | 3.70 | Long-term persistence of cellular hyporesponsiveness to filarial antigens after clearance of microfilaremia. ( Gopinath, R; Hanna, LE; Kavitha, V; Kumaraswami, V; Nutman, TB; Pillai, SV; Rajasekharan, A; Vijayasekaran, V, 1999) |
| "A microfilaria survey was conducted in Trinidad in 1992, 12 years after mass treatment with spaced doses of diethylcarbamazine citrate (DEC-C) for the control of Bancroftian filariasis; 348 persons were examined using thick blood smears and a membrane filtration technique." | 3.69 | Mass chemotherapy with diethylcarbamazine for the control of Bancroftian filariasis: a twelve-year follow-up in northern Trinidad, including observations on Mansonella ozzardi. ( Chadee, DD; Doon, R; Nathan, MB; Rawlins, SC; Tilluckdharry, CC, 1995) |
| "In the last ten years ivermectin appeared an efficient and safe alternative to diethylcarbamazine which is known to induce severe adverse reactions in loiasis, including encephalitis." | 3.69 | [Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin]. ( Boussinesq, M; Chippaux, JP; Ducorps, M; Gardon, J; Gardon-Wendel, N; Ndong, W; Ranque, S; Schneider, D, 1995) |
| " Adults were randomized into 2 treatment arms, DEC 6 mg/kg + ALB 400 mg (N = 12) or DEC 6 mg/kg + ALB 400 mg + IVM 200 μg/kg (N = 12), and monitored for microfilaria, parasite antigenemia, adverse events (AEs), and serum drug levels." | 2.82 | Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis. ( Baea, M; Fleckenstein, LL; Kazura, JW; King, CL; Lombore, B; Maki, E; Sanuku, N; Satofan, S; Schmidt, MS; Siba, PM; Thomsen, EK; Weil, GJ, 2016) |
| "Lymphatic filariasis is widely endemic in Myanmar." | 1.48 | The prevalence of lymphatic filariasis infection and disease following six rounds of mass drug administration in Mandalay Region, Myanmar. ( Aye, NN; Bradbury, RS; Dickson, BFR; Douglass, J; Graves, PM; McBride, WJ; Nwe, TW; Shwe, M; Wai, T; Win, SS, 2018) |
| "Loa-Loa is a parasitic infection endemic in the tropical rain forests of Western, Central, and Eastern Africa." | 1.32 | [Ocular involvement in systemic Loa-Loa filariasis. Case report and review of the literature]. ( Jaksche, A; Loeffler, KU; Martin, S; Wessels, L, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (41.18) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dickson, BFR | 1 |
| Graves, PM | 1 |
| Aye, NN | 1 |
| Nwe, TW | 1 |
| Wai, T | 1 |
| Win, SS | 1 |
| Shwe, M | 1 |
| Douglass, J | 1 |
| Bradbury, RS | 1 |
| McBride, WJ | 1 |
| Sankari, T | 1 |
| Hoti, SL | 1 |
| Das, LK | 2 |
| Govindaraj, V | 1 |
| Das, PK | 2 |
| Thomsen, EK | 1 |
| Sanuku, N | 1 |
| Baea, M | 1 |
| Satofan, S | 1 |
| Maki, E | 1 |
| Lombore, B | 1 |
| Schmidt, MS | 1 |
| Siba, PM | 1 |
| Weil, GJ | 1 |
| Kazura, JW | 1 |
| Fleckenstein, LL | 1 |
| King, CL | 1 |
| Moliner, JV | 1 |
| Valverde, AG | 1 |
| Sorolla, JM | 1 |
| Jaksche, A | 1 |
| Wessels, L | 1 |
| Martin, S | 1 |
| Loeffler, KU | 1 |
| Bregani, ER | 1 |
| Balzarini, L | 1 |
| Ghiringhelli, C | 1 |
| Tarsia, P | 1 |
| Meyrowitsch, DW | 2 |
| Simonsen, PE | 1 |
| Magesa, SM | 1 |
| Pani, SP | 1 |
| Reddy, GS | 1 |
| Vanamail, P | 2 |
| Venkatesvarlou, N | 1 |
| Vijayan, AP | 1 |
| Ramaiah, KD | 1 |
| Bordon, LM | 1 |
| Maurice, M | 1 |
| Chadee, DD | 1 |
| Tilluckdharry, CC | 1 |
| Rawlins, SC | 1 |
| Doon, R | 1 |
| Nathan, MB | 1 |
| Ducorps, M | 1 |
| Gardon-Wendel, N | 1 |
| Ranque, S | 1 |
| Ndong, W | 1 |
| Boussinesq, M | 1 |
| Gardon, J | 1 |
| Schneider, D | 1 |
| Chippaux, JP | 1 |
| Mukhopadhyay, S | 1 |
| Ravindran, B | 1 |
| Nguyen, DT | 1 |
| Hoang, TH | 1 |
| Nguyen, TD | 1 |
| Michael, E | 1 |
| Gopinath, R | 1 |
| Hanna, LE | 1 |
| Kumaraswami, V | 3 |
| Pillai, SV | 1 |
| Kavitha, V | 1 |
| Vijayasekaran, V | 1 |
| Rajasekharan, A | 1 |
| Nutman, TB | 1 |
| Shenoy, RK | 2 |
| Dalia, S | 1 |
| John, A | 2 |
| Suma, TK | 2 |
| Babu, BS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis[NCT04188301] | Phase 2 | 154 participants (Actual) | Interventional | 2019-12-06 | Completed | ||
| Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa[NCT01975441] | Phase 2 | 182 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis[NCT02899936] | 23,789 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis[NCT06070116] | Phase 2 | 300 participants (Anticipated) | Interventional | 2024-01-15 | Not yet recruiting | ||
| Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis[NCT03517462] | 231 participants (Actual) | Interventional | 2018-08-06 | Completed | |||
| A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis[NCT04410406] | Phase 3 | 164 participants (Actual) | Interventional | 2020-08-20 | Active, not recruiting | ||
| Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators[NCT03352206] | 20,092 participants (Actual) | Observational | 2017-10-18 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The effectiveness of three treatment regimens for killing adult female O. volvulus worms based on the percentage of all adult female worms in nodules that are alive 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment
| Intervention | Female worms in nodule (Count of Units) |
|---|---|
| IVM + ALB | 127 |
| IDA x 1 Dose | 142 |
| IDA x 3 Doses | 159 |
The effect of three treatment regimens for killing adult female O. volvulus worms will be compared based on the percentage of all adult female worms in nodules that are alive with embryos in the uterus 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
| Intervention | Female worms in nodules (Count of Units) |
|---|---|
| IVM + ALB | 127 |
| IDA x 1 Dose | 142 |
| IDA x 3 Doses | 159 |
The effect of three treatment regimens for sterilizing adult female O. volvulus worms will be compared based on the percentage of all adult female worms that are fertile in the nodules 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
| Intervention | Female worms with intact uterus (Count of Units) |
|---|---|
| IVM + ALB | 41 |
| IDA x 1 Dose | 40 |
| IDA x 3 Doses | 34 |
Rates of ocular adverse events of any grade within 3 months will be compared by treatment group. (NCT04188301)
Timeframe: within 3 months of treatment with IDA
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 4 |
| IDA x 1 Dose | 4 |
| IDA x 3 Doses | 3 |
Rates of adverse events grade 3 or higher that occur within 7 days of treatment in the subset of participants who have intraocular microfilariae just prior to treatment with IDA will be compared by treatment group. (NCT04188301)
Timeframe: within 7 days following end of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 0 |
| IDA x 1 Dose | 0 |
| IDA x 3 Doses | 0 |
Rates of severe adverse events (grade 3 or higher) following 1-day or 3-day triple drug treatment will be compared against those of the comparator regimen of 1 day of IVM/ALB. (NCT04188301)
Timeframe: Within 7 days following end of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 0 |
| IDA x 1 Dose | 0 |
| IDA x 3 Doses | 0 |
The effectiveness of three treatment regimens for preventing reappearance of microfilariae in the skin as determined by skin snips at 12 and 18 months after treatment will be compared by treatment arm. Measured by the presence of microfilariae in skin snips. (NCT04188301)
Timeframe: Baseline, 12 months, and 18 months following treatment
| Intervention | Count of microfilarae+ participants (Number) | ||
|---|---|---|---|
| Baseline | Month 12 | Month 18 | |
| IDA x 1 Dose | 6 | 21 | 15 |
| IDA x 3 Doses | 0 | 21 | 17 |
| IVM + ALB | 7 | 23 | 20 |
The effectiveness of three treatment regimens for complete clearance of microfilariae from the skin as determined by skin snips at 3, 12, and 18 months after treatment with IDA will be compared by treatment arm. (NCT04188301)
Timeframe: Baseline, 3 months, 12 months, & 18 months following treatment.
| Intervention | Count of Skin Microfilaria (Geometric Mean) | |||
|---|---|---|---|---|
| Baseline | Month 3 | Month 12 | Month 18 | |
| IDA x 1 Dose | 1.7 | 3 | 2.5 | 9.0 |
| IDA x 3 Doses | NA | 2.1 | 4.7 | 8.6 |
| IVM + ALB | 3.1 | 1.9 | 4.9 | 7.0 |
4 trials available for diethylcarbamazine and Parasitemia
| Article | Year |
|---|---|
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Tolerability and efficacy of single dose diethylcarbamazine (DEC) alone or co-administration with Ivermectin in the clearance of Wuchereria bancrofti microfilaraemia in Pondicherry, South India.
Topics: Adolescent; Adult; Animals; Antiparasitic Agents; Diethylcarbamazine; Double-Blind Method; Drug Ther | 2004 |
Treatment of the microfilaraemia of asymptomatic brugian filariasis with single doses of ivermectin, diethylcarbamazine or albendazole, in various combinations.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Brugia malayi; Diethylcarbamazine; Drug Administratio | 1999 |
Two-year follow-up of the microfilaraemia of asymptomatic brugian filariasis, after treatment with two, annual, single doses of ivermectin, diethylcarbamazine and albendazole, in various combinations.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Brugia malayi; Diethylcarbamazine; Drug Administratio | 2000 |
13 other studies available for diethylcarbamazine and Parasitemia
| Article | Year |
|---|---|
The prevalence of lymphatic filariasis infection and disease following six rounds of mass drug administration in Mandalay Region, Myanmar.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Animals; Child; Child, Preschool; Cross-Sec | 2018 |
Effect of Diethylcarbamazine (DEC) on prostaglandin levels in Wuchereria bancrofti infected microfilaraemics.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Diethylcarbamazine; Dinoprostone; Elephantiasis, Filarial; Fi | 2013 |
[Loa loa meningoencephalitis secondary to treatment with mebendazol].
Topics: Adolescent; Albendazole; Animals; Anthelmintics; Brain Damage, Chronic; Central Nervous System Helmi | 2011 |
[Ocular involvement in systemic Loa-Loa filariasis. Case report and review of the literature].
Topics: Adult; Africa, Central; Animals; Combined Modality Therapy; Conjunctival Diseases; Diethylcarbamazin | 2004 |
Transfusional Mansonella perstans microfilariasis.
Topics: Animals; Antimalarials; Blood Donors; Carrier State; Diethylcarbamazine; Disease Transmission, Infec | 2003 |
Long-term effect of three different strategies for mass diethylcarbamazine administration in bancroftian filariasis: follow-up at 10 years after treatment.
Topics: Adolescent; Adult; Animals; Child; Diethylcarbamazine; Drug Administration Schedule; Endemic Disease | 2004 |
Changes in Wuchereria bancrofti infection in a highly endemic community following 10 rounds of mass administration of diethylcarbamazine.
Topics: Adult; Aged; Animals; Antigens, Helminth; Child; Child, Preschool; Cross-Sectional Studies; Diethylc | 2007 |
Traveller's loiasis in Zimbabwe: a case report.
Topics: Adult; Diethylcarbamazine; Female; Humans; Loiasis; Parasitemia; Travel; Zimbabwe | 1994 |
Mass chemotherapy with diethylcarbamazine for the control of Bancroftian filariasis: a twelve-year follow-up in northern Trinidad, including observations on Mansonella ozzardi.
Topics: Adolescent; Adult; Age Distribution; Animals; Child; Child, Preschool; Diethylcarbamazine; Female; F | 1995 |
[Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].
Topics: Adult; Aged; Animals; Arthralgia; C-Reactive Protein; Cameroon; Diethylcarbamazine; Female; Fever; F | 1995 |
Antibodies to diethylcarbamazine potentiate the antifilarial activity of the drug.
Topics: Aedes; Animals; Antibodies; Brugia malayi; Diethylcarbamazine; Female; Filariasis; Filaricides; Male | 1997 |
A review of the present status of lymphatic filariasis in Vietnam.
Topics: Animals; Brugia malayi; Cats; Culicidae; Data Collection; Diethylcarbamazine; Disease Reservoirs; El | 1998 |
Long-term persistence of cellular hyporesponsiveness to filarial antigens after clearance of microfilaremia.
Topics: Adult; Animals; Antigens, Helminth; Diethylcarbamazine; Drug Therapy, Combination; Female; Filariasi | 1999 |